AB 1460: California's 340B Contract Pharmacy Protection Bill Expected to Return in 2026
AB 1460 (Assemblymember Chris Rogers, D-Santa Rosa) would prohibit pharmaceutical manufacturers from restricting 340B contract pharmacy arrangements. The bill passed the Assembly in 2025 but stalled in the Senate.
It's expected to return in 2026. Eight states have enacted similar laws; 23 have pending bills. For rural FQHCs, passage would expand access to 340B pharmacy discounts. However, the IRA is simultaneously creating structural pressure: 340B hit $81B in 2024 (+23% YoY), and Medicare Part D/B manufacturer rebate exemptions begin impacting 340B margins in 2026.
Key takeaways
- AB 1460 would prohibit pharma manufacturers from restricting 340B contract pharmacy arrangements
- Passed Assembly in 2025, stalled in Senate — expected to return in 2026
- 8 states enacted similar laws; 23 have pending bills — critical for rural FQHCs
- 340B hit $81B in 2024 (+23% YoY) — IRA rebate exemptions begin impacting margins in 2026
Primary source
McDermott Will & Emery / California LegislatureFQHC Talent. (2026, March 9). AB 1460: California's 340B Contract Pharmacy Protection Bill Expected to Return in 2026. Primary source: McDermott Will & Emery / California Legislature. Retrieved June 12, 2026, from https://www.fqhctalent.com/intel/ab-1460-340b-contract-pharmacy-2026
More in Legislation
Jun 10
The work-requirement map, 6 months out: 4 states going early, Nebraska's freeze is the preview, and Georgia's 5% enrollment rate is the warning
Jun 10
MACPAC's June report hands FQHCs two federal hooks: a work-requirement monitoring mandate and a human-review requirement for AI prior-auth denials
Jun 9
Washington's 340B protection law survives — and the national map now splits clean: 22 state laws, two circuits upholding, one blocking, DOJ siding with manufacturers
Jun 5
Becerra Tops the June 2 Governor Primary and Advances to November — Putting a Former HHS Secretary in Reach of the Office, but Not Until After the December Cliff